Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis

NCT05798520 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05798520
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05798520 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-Part, Multicenter, Randomized, Blinded, Active-Controlled Phase 2 Study to Sequentially Evaluate the Safety and Efficacy of BIIB091 Monotherapy and BIIB091 Combination Therapy With Diroximel Fumarate in Participants With Relapsing Forms of Multiple Sclerosis
Lead sponsor
Biogen
Phase
Phase 2
Overall status
Completed
Start date
July 25, 2023
Completion date
February 10, 2026
Enrollment
127 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing forms of multiple sclerosis